SHM Converge Scientific Abstract ePoster Gallery-Exploring the Association Between Comorbidities, Antidiabetic Medication and Fibrosis Risk With Cardiovascular Outcomes in Masld: A Restrospective Study

Exploring the Association Between Comorbidities, Antidiabetic Medication and Fibrosis Risk With Cardiovascular Outcomes in Masld: A Restrospective Study

Back to course

Pdf Summary

This retrospective cross-sectional study examined 13,787 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) at Lincoln Medical Center to assess how comorbidities, medications, and fibrosis risk relate to cardiovascular outcomes. Patients were identified through electronic health records and stratified by FIB-4 score into low-risk and moderate-risk fibrosis groups. The main outcome was a combined cardiovascular endpoint, including congestive heart failure (CHF), coronary artery disease (CAD), and peripheral artery disease (PAD). Multivariable logistic regression was used to calculate odds ratios for comorbidities such as hypertension (HTN), diabetes mellitus (DM), dyslipidemia, and obesity, as well as medication use including statins, ezetimibe, and antidiabetic drugs.<br /><br />The results showed that HTN was the strongest predictor of cardiovascular events overall, with an odds ratio (OR) of 8.80, followed by DM (OR 4.73) and dyslipidemia (OR 2.98). In the moderate-fibrosis-risk group, only HTN and DM remained significant predictors. Medication use was also associated with higher odds of cardiovascular endpoints: in low-risk patients, statins, ezetimibe, and diabetic medications were all significantly linked to increased odds of events, and these associations persisted in the moderate-risk group.<br /><br />The authors conclude that HTN and DM are the most important comorbidity predictors of cardiovascular outcomes in MASLD, especially among patients with moderate fibrosis risk. They also found strong associations between cardiovascular endpoints and use of lipid-lowering and antidiabetic medications, particularly in low-risk patients. The study suggests that cardiovascular risk in MASLD may vary with fibrosis severity and comorbidity burden, but further research is needed to clarify confounding factors and determine causality.

Asset Subtitle

Daniel Alejandro Gonzalez Mosquera

Meta Tag

Author List Alexander Mandadjiev, Danelly Gomez D' Aza, Daniel Alejandro Gonzalez Mosquera, Han Oo, Mariana Nunes Ferreira, Vidya Menon, Zahra Tasneem

Category Research

Concept MASLD

Concept Cardiovascular Outcomes

Concept Hypertension

Concept Diabetes Mellitus

Concept Fibrosis

Distinguished Non-Finalist

Presenter Organization Lincoln Medical Center

Presenting Author Daniel Alejandro Gonzalez Mosquera

Track Outcomes Research

Keywords

MASLD

cardiovascular outcomes

fibrosis risk

FIB-4 score

hypertension

diabetes mellitus

dyslipidemia

statins

ezetimibe

antidiabetic medications

MASLD

Cardiovascular Outcomes

Hypertension

Diabetes Mellitus

Fibrosis